Omeros (NASDAQ:OMER) Director Sells $189,500.00 in Stock

Omeros Corporation (NASDAQ:OMER) Director Arnold Hanish sold 10,000 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $18.95, for a total value of $189,500.00. Following the completion of the sale, the director directly owned 5,000 shares in the company, valued at approximately $94,750. This represents a 66.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Omeros Price Performance

Omeros stock opened at $18.61 on Monday. The stock has a fifty day moving average price of $12.64 and a two-hundred day moving average price of $12.03. Omeros Corporation has a 52-week low of $3.94 and a 52-week high of $19.65. The firm has a market capitalization of $1.35 billion, a P/E ratio of 14.54 and a beta of 2.54.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. On average, equities research analysts predict that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on OMER shares. Weiss Ratings upgraded shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Zacks Research downgraded Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, HC Wainwright reissued a “buy” rating on shares of Omeros in a research note on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Hedge Funds Weigh In On Omeros

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMER. Acadian Asset Management LLC acquired a new position in Omeros during the first quarter worth $357,000. XTX Topco Ltd bought a new stake in Omeros during the 2nd quarter worth about $191,000. Invesco Ltd. lifted its position in Omeros by 34.1% during the 2nd quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock worth $350,000 after buying an additional 29,644 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of Omeros by 15.1% during the 2nd quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock worth $2,224,000 after buying an additional 97,224 shares during the last quarter. Finally, Sei Investments Co. bought a new position in shares of Omeros in the 2nd quarter valued at about $40,000. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.